Short-term prophylaxis in a patient with acquired C1-INH deficiency - 01/08/14
Disclosure of potential conflict of interest: H. Farkas is a board member for and has received consultancy fees, lecture fees, and travel support from CSL Behring, Shire Human Genetic Therapies, Pharming, and Viropharma. D. Csuka and L. Varga have received travel support from Shire Human Genetic Therapies, Viropharma, and CSL Behring. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 134 - N° 2
P. 478-480 - août 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?